Heather Kuriger
Nurse Practitioner · Brandon, MSNPI 1609181882
Payments from drug & device makers
Across 614 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- GSK$1K
- Lilly USA, LLC$813
- Pfizer$740
- AstraZeneca$715
- plus $5K from 31 others
What the payments were for
- Food & beverage$11,204100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $1,969 |
| Novo Nordisk | 71 | $1,421 |
| GSK | 58 | $1,004 |
| Lilly USA, LLC | 58 | $813 |
| Pfizer | 43 | $740 |
| AstraZeneca | 28 | $715 |
| Bayer | 29 | $606 |
| Abbott | 32 | $476 |
| Esperion Therapeutics, Inc. | 20 | $446 |
| Corcept Therapeutics | 14 | $356 |
| Amgen | 21 | $340 |
| Boehringer Ingelheim | 15 | $330 |
| Johnson & Johnson | 15 | $224 |
| Biohaven Pharmaceuticals, Inc. | 6 | $207 |
| Novartis | 11 | $187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $185 |
| Merck | 8 | $133 |
| Teva Pharmaceuticals USA, Inc. | 9 | $129 |
| Sanofi-aventis U.S. LLC | 9 | $117 |
| Exact Sciences | 7 | $117 |
| E.r. Squibb & Sons, L.L.C. | 7 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $92 |
| Rhythm Pharmaceuticals, Inc. | 1 | $84 |
| Shield Therapeutics Inc | 4 | $65 |
| Nxstage Medical, Inc. | 1 | $64 |
| Inspire Medical Systems, Inc. | 2 | $48 |
| Astellas Pharma US Inc | 3 | $47 |
| Currax Pharmaceuticals LLC | 3 | $45 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,216 in reported general payments places this provider in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 123 | $116,489 |
| OzempicSemaglutide | 68 | $80,376 |
| JardianceEmpagliflozin | 33 | $42,727 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $25,074 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $24,182 |
| XareltoRivaroxaban | 25 | $21,272 |
| TrulicityDulaglutide | 21 | $20,163 |
| MounjaroTirzepatide | 15 | $15,329 |
| RexultiBrexpiprazole | 11 | $15,142 |
| EntrestoSacubitril/Valsartan | 13 | $12,472 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $12,097 |
| Repatha SureclickEvolocumab | 14 | $7,497 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,709 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,066 |
| Levemir FlexpenInsulin Detemir | 20 | $3,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $740 | $116,489123 claims |
| Novo NordiskOzempic | $1,421 | $80,37668 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat | $330 | $61,53261 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $813 | $35,49136 claims |
| GSKTrelegy Ellipta | $1,004 | $25,07429 claims |
| Johnson & JohnsonXarelto | $224 | $21,27225 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $17 | $15,14211 claims |
| NovartisEntresto | $187 | $12,47213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $185 | $5,06611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $1,093133 claims |
| AbbVieSynthroid | $1,969 | $99416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.
Other nurse practitioner in Brandon
- Erin BassBrandon$9K
- Shelly BilbroBrandon$8K
- Cara RobbBrandon$6K
- Christina TreppendahlRidgeland$673K
- Catherine WellsJackson$75K
- Jo Anna WarrenJackson$73K
- Marisa StringerBiloxi$68K
- Sara KlausFlowood$48K
- Micaela PerkinsOxford$32K
- Michelle TharpJackson$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.